Hunan Er-Kang Pharmaceutical (300267.SZ) Earnings Analysis

Hunan Er-Kang Pharmaceutical (300267.SZ) has no confirmed upcoming earnings date. Trailing P/E -16.06.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 300267.SZ next report earnings?

No confirmed upcoming earnings date is currently scheduled for 300267.SZ. This page updates as the calendar is published.

300267.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2025-09-290.00094 CNYn/an/an/a
2025-06-300.00461 CNYn/an/an/a
2025-05-16-0.16848 CNYn/an/an/a
2025-03-310.0136 CNYn/an/an/a
2024-09-28-0.0154 CNYn/an/an/a

300267.SZ valuation and analyst view

Trailing P/E-16.06
Trailing EPS-0.19142 CNY
Price / book1.55
Dividend yield0.00%
Market cap6.00B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is Hunan Er-Kang Pharmaceutical (300267.SZ)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 300267.SZ. This page updates as the calendar is published.

Did 300267.SZ beat earnings last quarter?

Consensus estimate data was not available for 300267.SZ's 2025-09-29 report.

What is 300267.SZ's current P/E ratio and EPS?

300267.SZ trades at a trailing P/E of -16.06 on trailing EPS of -0.1914189357072545 CNY.

What do analysts rate 300267.SZ?

300267.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.